查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1464691

病毒载体和质粒 DNA 製造市场，按载体类型、工作流程、应用、最终用途、治疗领域、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Viral Vector and Plasmid DNA Manufacturing Market, By Vector Type, By Workflow, By Application, By End-use, By Therapeutic Area, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 345 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2023 年病毒载体和质粒 DNA 製造市场规模为 54.05 亿美元，2024 年至 2032 年复合年增长率为 19.7%。

病毒载体与质粒 DNA 製造市场-市场动态

增加政府对细胞研究的支持以推动市场需求

由于政府增加了创建用于生产病毒载体的新技术和设施的资助，从而增加了整体研究活动并支持了基于细胞的研究，病毒载体和质粒 DNA 製造市场预计将成长。此外，推动市场扩张的主要驱动力是癌症和心臟异常等疾病的日益普及、细胞疗法研究的使用以及病毒载体和质粒 DNA 製造领域的技术进步。例如，加拿大政府对基因组学和再生医学进行投资，以促进公民的健康。透过干细胞网路的竞争性研究资助计划，获得了 430 万美元。这笔直接资金将支持加拿大各地旨在治疗多发性硬化症、肌肉萎缩症、癌症、血液疾病、1 型糖尿病、心臟病和囊性纤维化等健康问题的 16 项措施。本次竞赛的资助机会之一是一项新计划，旨在帮助健康、生物工程和社会科学领域的早期职业研究人员创建干细胞研究计划，重点关注再生医学。此外，加拿大基因组公司也将为十项新的基因组学研究提供 1,600 万加元。到2035年，这项投资将有助于生物医学和药物开发的转型。它还将支持具有直接应用潜力的任务驱动研究，解决农业、健康和环境领域的现实问题和可能性。

不断增加的产品发布为市场收入成长提供了潜在机会

预计不断增加的产品推出将为预测期内的市场成长提供潜在机会。例如，2023 年 3 月，透过引入 Charles River Laboratories International, Inc. 的现成 pHelper，现在可以更有效地管理基于腺相关病毒 (AAV) 的基因治疗计划，从早期发现到商业化生产服务。研究级 (RG)、高品质 (HQ) 和良好生产规范 (GMP) 等级均可立即获得。

病毒载体和质粒 DNA 製造市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 19.7% 左右的复合年增长率成长

基于载体类型细分，腺相关病毒（AAV）细分市场预计将在预测期内占据最大的市场份额

根据工作流程细分，下游製造领域预计将在预测期内占据重要的市场份额

根据治疗领域，肿瘤疾病领域预计将在预测期内占据显着的市场份额

按地区划分，北美是 2023 年的主要收入来源

病毒载体和质粒 DNA 製造市场区隔分析：

全球病毒载体和质粒 DNA 製造市场根据载体类型、工作流程、应用、最终用途、治疗领域和地区进行细分。

根据载体类型，病毒载体和质粒DNA製造市场分为腺病毒、慢病毒、腺相关病毒（AAV）、逆转录病毒、质粒、桿状病毒、仙台病毒和其他（单纯疱疹病毒（HSV）等） 。腺相关病毒（AAV）领域预计将在预测期内占据最大的市场份额。由于 AAV 在将基因递送到所需位置方面具有极高的精确度，因此备受追捧，并正在快速用于临床试验。关于骨科和眼科基因治疗药物开发的临床研究显示疗效和效率提高，这是越来越多采用的原因。

根据工作流程，病毒载体和质粒 DNA 製造业分为上游製造和下游製造。由于用于抛光和纯化治疗级最终产品的极其复杂的工艺，预计下游製造部门将在预计期间占据重要的市场份额。

根据应用，市场分为反义和 RNAi 治疗、疫苗学、基因治疗、组织工程、细胞治疗、研究应用和其他（生物感测器等）。

根据最终用途，该行业分为製药和生物製药公司、合约製造组织（CMO、研究机构和其他（政府机构等））。

根据治疗领域，病毒载体和质粒 DNA 製造市场分为神经疾病、感觉疾病、肌肉骨骼疾病、代谢疾病、肿瘤疾病、罕见疾病、血液疾病、免疫疾病和其他（生殖健康等）。预计肿瘤疾病领域将在预测期内占据显着的市场份额。该细分市场的成长归因于全球癌症盛行率的上升。例如，根据国际癌症研究机构 (IARC) 的最新估计，预计 2022 年将新增 2,000 万癌症病例，并有 970 万人死于该疾病。五分之一的人会在一生中的某个阶段罹患癌症；九分之一的男性和十二分之一的女性将死于这种疾病。因此，上述统计数据推动了细分市场的扩张。

病毒载体和质粒 DNA 製造市场 - 地理洞察

从地理来看，该市场广泛分布于北美、拉丁美洲、欧洲、亚太、中东和非洲等地区。这些区域根据开展业务的国家进一步划分。预计北美将在预测期内占据最大的市场份额。这是因为该领域的合约开发组织数量不断增加，以及企业越来越多地参与基因和细胞治疗研究和产品开发。此外，区域公司正在该地区发展其生产工厂。由于有重要的市场参与者，例如提供 GMP 製造服务的 CDMO，以及使用高度创造性的製造方法进行生产，美国在北美病毒载体和质粒 DNA 製造市场中占有最大的收入份额。

病毒载体与质粒 DNA 製造市场-竞争格局：

几家主要企业正在实施一些策略性努力，以提高其市场地位并为客户提供广泛的服务。为了提高市场占有率和收入并获得竞争优势，组织经常参与合作伙伴关係和协议、合资企业、扩张、服务推出、产品创新和其他推动市场成长的策略。近年来，质粒 DNA 和病毒载体市场出现了显着的创新。质粒 DNA 和病毒载体的生产商不断寻找新的有效解决方案，以满足对增强基因疗法和疫苗开发不断增长的需求。使用瞬时转染技术大规模生产病毒载体是该市场的主要发展之一。利用悬浮细胞培养技术生产病毒载体是另一种创新方法。大型生物技术和製药公司正在更频繁地收购小型载体和质粒 DNA 生产商，以获得其专利技术、知识和製造能力。结果，出现了市场整合，增加了老牌企业在定价和市场份额方面的权力。透过利用大型收购方的基础设施和资源，小型企业可以扩大业务并进入新市场。例如，2022年2月，Exelead被默克公司以约7.8亿美元收购。沿着 mRNA 价值链为最终用户提供完整的端对端 CDMO 服务将进一步改善默克的生命科学产品。

最近的发展：

2023 年 10 月，AGC Biologics 宣布扩建其德国 pDNA 製造厂。预计这将有助于企业缩短製造交货时间。

目录

第一章：病毒载体和质粒 DNA 製造市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按载体类型分類的病毒载体和质粒 DNA 製造市场片段
    • 按工作流程分類的病毒载体和质粒 DNA 製造市场片段
    • 按应用分類的病毒载体和质粒 DNA 製造市场片段
    • 以最终用途分類的病毒载体和质粒 DNA 製造市场片段
    • 按治疗领域分類的病毒载体和质粒 DNA 製造市场片段
    • 按国家/地区分類的病毒载体和质粒 DNA 製造市场片段
    • 按地区分類的病毒载体和质粒 DNA 製造市场片段
  • 竞争洞察

第 3 章：病毒载体和质粒 DNA 製造主要市场趋势

  • 病毒载体和质粒 DNA 製造市场驱动因素
    • 市场驱动因素的影响分析
  • 病毒载体和质粒 DNA 製造市场限制
    • 市场限制影响分析
  • 病毒载体和质粒 DNA 製造市场机会
  • 病毒载体与质粒 DNA 製造市场未来趋势

第 4 章：病毒载体与质粒 DNA 製造业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：病毒载体与质粒 DNA 製造市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：病毒载体与质粒 DNA 製造市场格局

  • 2023 年病毒载体和质粒 DNA 製造市场份额分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：病毒载体和质粒 DNA 製造市场 - 按载体类型

  • 概述
    • 按向量类型分類的细分市场占有率分析
    • 腺病毒
    • 慢病毒
    • 腺相关病毒 (AAV)
    • 逆转录病毒
    • 质粒
    • 桿状病毒
    • 仙台病毒
    • 其他（单纯疱疹病毒（HSV）等）

第 8 章：病毒载体和质粒 DNA 製造市场 - 按工作流程

  • 概述
    • 按工作流程分類的细分市场占有率分析
    • 上游製造
      • 向量放大和扩展
      • 载体恢復/收穫
    • 下游製造
      • 纯化
      • 填充完成

第 9 章：病毒载体和质粒 DNA 製造市场 - 按应用

  • 概述
    • 按应用分類的细分市场占有率分析
    • 反义和 RNAi 治疗
    • 疫苗学
    • 基因治疗
    • 组织工程
    • 细胞疗法
    • 研究应用
    • 其他（生物感测器等）

第 10 章：病毒载体和质粒 DNA 製造市场 - 按最终用途

  • 概述
    • 按最终用途分類的细分市场份额分析
    • 製药和生物製药公司
    • 合约製造组织 (CMO)
    • 研究机构
    • 其他（政府机构等）

第 11 章：病毒载体和质粒 DNA 製造市场 - 按治疗领域

  • 概述
    • 按治疗领域分類的细分市场占有率分析
    • 神经系统疾病
    • 感觉障碍
    • 肌肉骨骼疾病
    • 代谢紊乱
    • 肿瘤疾病
    • 罕见疾病
    • 血液疾病
    • 免疫系统疾病
    • 其他（生殖健康等）

第 12 章：病毒载体和质粒 DNA 製造市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美病毒载体和质粒 DNA 製造主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按向量类型）
    • 北美市场规模和预测（按工作流程）
    • 北美市场规模和预测（按应用）
    • 北美市场规模和预测（按最终用途）
    • 北美市场规模与预测（按治疗领域）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲病毒载体和质粒 DNA 製造主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按向量类型）
    • 欧洲市场规模和预测（按工作流程）
    • 欧洲市场规模和预测（按应用）
    • 欧洲市场规模和预测（按最终用途）
    • 欧洲市场规模与预测（按治疗领域）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区病毒载体和质粒 DNA 製造主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按向量类型）
    • 亚太地区市场规模和预测（按工作流程）
    • 亚太地区市场规模与预测（按应用）
    • 亚太地区市场规模和预测（按最终用途）
    • 按治疗领域分類的亚太市场规模和预测
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲病毒载体和质粒 DNA 製造主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按向量类型）
    • 拉丁美洲市场规模和预测（按工作流程）
    • 拉丁美洲市场规模与预测（按应用）
    • 拉丁美洲市场规模和预测（按最终用途）
    • 拉丁美洲市场规模与预测（按治疗领域）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲病毒载体和质粒 DNA 製造主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按向量类型）
    • 中东和非洲市场规模及预测（按工作流程）
    • 中东和非洲市场规模及预测（按应用）
    • 中东和非洲市场规模和预测（按最终用途）
    • 中东和非洲市场规模及预测（按治疗领域）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 13 章：主要供应商分析 - 病毒载体和质粒 DNA 製造业

  • 竞争仪表板
  • 公司简介
    • CEVEC Pharmaceuticals
    • Catalent Biologics
    • Cobra Biologics
    • Altruist Biotechnology
    • NorthX Biologics
    • Novartis
    • BioReliance (a subsidiary of Merck KGaA)
    • Centre for Process Innovation
    • Wuxi AppTech
    • Charles River Laboratories
    • CoJourney
    • Esco Aster
    • Jiangsu Puxin Biopharmaceutical
    • Lonza
    • Advanced BioScience Laboratories
    • AGC Biologics
    • Aldevron
    • Biovian
    • Celonic
    • BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)
    • Oxford BioMedica
    • Sanofi
    • Thermo Fisher Scientific
    • VectorBuilder
    • Matica Biotechnology
    • Resilience
    • Nikon CeLL innovation

第 14 章：360 度分析师视角

第 15 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV2473

REPORT HIGHLIGHT

Viral Vector and Plasmid DNA Manufacturing Market size was valued at USD 5,405 Million in 2023, expanding at a CAGR of 19.7% from 2024 to 2032.

Viral vectors and plasmid DNA can be employed in gene therapy to treat a wide range of diseases, such as cancer, metabolic issues, cardiac problems, and neurological disorders. As viral vectors are based on baculovirus, herpes simplex viruses, adenoviruses, and other viruses, they are being employed increasingly frequently in vaccine research and the development of novel medications.

Viral Vector and Plasmid DNA Manufacturing Market- Market Dynamics

Increasing government support for cell-based research to propel market demand

The market for Viral Vector and Plasmid DNA Manufacturing is expected to grow as a result of increased government funding for the creation of new technologies and facilities for producing viral vectors, which has increased overall research activity and supported cell-based research. In addition, the main drivers propelling market expansion are the growing prevalence of diseases including cancer and heart abnormalities, the use of cell therapies research, and technological advancements in the field of viral vector & plasmid DNA manufacture. For instance, the Canadian government made investments in genomics and regenerative medicine to promote the health of its citizens. Through the competitive research funding initiative of the Stem Cell Network, $4.3 million was awarded. 16 initiatives from around Canada that aim to treat health issues like multiple sclerosis, muscular dystrophy, cancer, blood diseases, diabetes type 1, heart disease, and cystic fibrosis will be supported by this direct funding. A new program to assist early career researchers in the health, bioengineering, and social sciences who are creating stem cell research initiatives with an emphasis on regenerative medicine was one of the funding opportunities featured in this competition. In addition, $16 million will be provided to ten new genomics studies through Genome Canada. By 2035, this investment will have contributed to the transformation of biomedicine and drug development. It will also support mission-driven research with direct application potential that tackles real-world problems and possibilities in the fields of agriculture, health, and the environment.

Rising product launches offer a potential opportunity for market revenue growth

The increasing product launch is expected to offer a potential opportunity for market growth during the forecast period. For instance, in March 2023, Adeno-associated virus (AAV)-based gene therapy initiatives can now be more efficiently managed from early discovery to commercial manufacture with the introduction of Charles River Laboratories International, Inc.'s off-the-shelf pHelper service. Research Grade (RG), High Quality (HQ), and Good Manufacturing Practice (GMP) grades are all instantly available.

Viral Vector and Plasmid DNA Manufacturing Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.7% over the forecast period (2024-2032)

Based on vector type segmentation, the Adeno-Associated Virus (AAV) segment is expected to hold the largest market share over the forecast period

Based on workflow segmentation, the Downstream Manufacturing segment is expected to hold a significant market share over the projected period

Based on the therapeutic area, the oncological disorder segment is expected to hold a prominent market share over the forecast period

Based on region, North America was the leading revenue generator in 2023

Viral Vector and Plasmid DNA Manufacturing Market- Segmentation Analysis:

The Global Viral Vector and Plasmid DNA Manufacturing Market is segmented based on Vector Type, Workflow, Application, End-use, Therapeutic Area, and Region.

Based on the vector type, the Viral Vector and Plasmid DNA Manufacturing market is segmented into Adenovirus, Lentivirus, Adeno-Associated Virus (AAV), Retrovirus, Plasmids, Baculovirus, Sendai Virus and Others (Herpes Simplex Virus (HSV), etc.). The Adeno-Associated Virus (AAV) segment is expected to hold the largest market share over the forecast period. Due to their exceptional precision in delivering the gene to the desired location, AAVs are extremely sought after and are being used in clinical trials at a rapid pace. Clinical investigations about the development of orthopedic and ophthalmic gene therapy medicines are showing enhanced efficacy and efficiency, which is the reason for the increasing adoption.

Based on the workflow, the Viral Vector and Plasmid DNA Manufacturing industry is bifurcated into Upstream Manufacturing and Downstream Manufacturing. The Downstream Manufacturing segment is expected to hold a significant market share over the projected period due to the extremely intricate processes used to polish and purify final products of therapeutic grade.

Based on the application, the market is bifurcated into Antisense & RNAi Therapy, Vaccinology, Gene Therapy, Tissue Engineering, Cell Therapy, Research Applications and Others (Biosensors, etc.).

Based on the end-use, the industry is bifurcated into Pharmaceutical and Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs, Research Institutes and Others (Government Agencies, etc.).

Based on the therapeutic area, the Viral Vector and Plasmid DNA Manufacturing market is bifurcated into Neurological Disorders, Sensory Disorders, Musculoskeletal Disorders, Metabolic Disorders, Oncological Disorders, Rare Diseases, Blood Disorders, Immunological Disorders and Others (Reproductive Health, etc.). The oncological disorder segment is expected to hold a prominent market share over the forecast period. The segment growth is attributed to the rising prevalence of cancer across the globe. For instance, according to the latest estimates by the International Agency for Research on Cancer (IARC), 20 million new instances of cancer and 9.7 million deaths from the disease are anticipated for 2022. 53.5 million people were predicted to still be alive five years after receiving a cancer diagnosis. One in five people will have cancer at some point in their lives; one in nine men and one in twelve women will pass away from the disease. Thus, the aforementioned statistics propel the segment expansion.

Viral Vector and Plasmid DNA Manufacturing Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to hold the largest market share over the forecast period. This is explained by the increasing number of contract development organizations in the area as well as the increasing involvement of businesses in gene and cell therapy research and product development. Furthermore, regional companies are growing their production plants in the area. Due to the existence of significant market participants, such as CDMOs providing GMP manufacturing services, and the use of highly creative manufacturing methods for production, the United States held the largest revenue share in the North American market for viral vectors and plasmid DNA manufacturing.

Viral Vector and Plasmid DNA Manufacturing Market- Competitive Landscape:

Several major businesses are implementing some strategic efforts to improve their market position and provide a wide range of services to customers. To boost market presence and revenue and obtain a competitive edge, organizations frequently engage in partnerships and agreements, joint ventures, expansion, service launches, product innovation and other tactics that fuel market growth. Recent years have seen a notable level of innovation in the market for plasmid DNA and viral vectors. Producers of plasmid DNA and viral vectors are continuously looking for new and effective solutions to meet the growing demand for enhanced gene therapy and vaccine development. The use of transient transfection technology for the large-scale manufacturing of viral vectors is one of the major developments in this market. Utilizing suspension cell culture techniques to produce viral vectors is another innovative approach. Big biotech and pharmaceutical corporations are buying up smaller vector and plasmid DNA producers more frequently to gain access to their patented technologies, knowledge, and manufacturing capabilities. As a result, there is market consolidation, which increases the power of established players over pricing and market share. By utilizing the infrastructure and resources of larger acquirers, smaller businesses can expand their operations and reach new markets. For instance, in February 2022, Exelead was purchased by Merck KGaA for around USD 780 million. Providing end users with full end-to-end CDMO services along the mRNA value chain would further improve Merck's Life Science offering.

Recent Developments:

In October 2023, AGC Biologics announced the expansion of their German pDNA manufacturing facility. It is anticipated that this will assist the business in shortening the manufacturing lead time.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

CEVEC Pharmaceuticals

Catalent Biologics

Cobra Biologics

Altruist Biotechnology

NorthX Biologics

Novartis

BioReliance (a subsidiary of Merck KGaA)

Centre for Process Innovation

Wuxi AppTech

Charles River Laboratories

CoJourney

Esco Aster

Jiangsu Puxin Biopharmaceutical

Lonza

Advanced BioScience Laboratories

AGC Biologics

Aldevron

Biovian

Celonic

BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)

Oxford BioMedica

Sanofi

Thermo Fisher Scientific

VectorBuilder

Matica Biotechnology

Resilience

Nikon CeLL innovation

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE- MARKET ANALYSIS, 2019 - 2032

  • Adenovirus
  • Lentivirus
  • Adeno-Associated Virus (AAV)
  • Retrovirus
  • Plasmids
  • Baculovirus
  • Sendai Virus
  • Others (Herpes Simplex Virus (HSV), etc.)

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW- MARKET ANALYSIS, 2019 - 2032

  • Upstream Manufacturing
  • Vector Amplification & Expansion
  • Vector Recovery/Harvesting
  • Downstream Manufacturing
  • Purification
  • Fill Finish

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Antisense & RNAi Therapy
  • Vaccinology
  • Gene Therapy
  • Tissue Engineering
  • Cell Therapy
  • Research Applications
  • Others (Biosensors, etc.)

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END-USE- MARKET ANALYSIS, 2019 - 2032

  • Pharmaceutical and Biopharmaceutical Companies
  • Contract Manufacturing Organizations (CMOs)
  • Research Institutes
  • Others (Government Agencies, etc.)

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Neurological Disorders
  • Sensory Disorders
  • Musculoskeletal Disorders
  • Metabolic Disorders
  • Oncological Disorders
  • Rare Diseases
  • Blood Disorders
  • Immunological Disorders
  • Others (Reproductive Health, etc.)

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Viral Vector and Plasmid DNA Manufacturing Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Vector Type
    • 2.1.2. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Workflow
    • 2.1.3. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Application
    • 2.1.4. Viral Vector and Plasmid DNA Manufacturing Market Snippet by End-use
    • 2.1.5. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Therapeutic Area
    • 2.1.6. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Country
    • 2.1.7. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Region
  • 2.2. Competitive Insights

3. Viral Vector and Plasmid DNA Manufacturing Key Market Trends

  • 3.1. Viral Vector and Plasmid DNA Manufacturing Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Viral Vector and Plasmid DNA Manufacturing Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Viral Vector and Plasmid DNA Manufacturing Market Opportunities
  • 3.4. Viral Vector and Plasmid DNA Manufacturing Market Future Trends

4. Viral Vector and Plasmid DNA Manufacturing Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Viral Vector and Plasmid DNA Manufacturing Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Viral Vector and Plasmid DNA Manufacturing Market Landscape

  • 6.1. Viral Vector and Plasmid DNA Manufacturing Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Viral Vector and Plasmid DNA Manufacturing Market - By Vector Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Vector Type, 2023 & 2032 (%)
    • 7.1.2. Adenovirus
    • 7.1.3. Lentivirus
    • 7.1.4. Adeno-Associated Virus (AAV)
    • 7.1.5. Retrovirus
    • 7.1.6. Plasmids
    • 7.1.7. Baculovirus
    • 7.1.8. Sendai Virus
    • 7.1.9. Others (Herpes Simplex Virus (HSV), etc.)

8. Viral Vector and Plasmid DNA Manufacturing Market - By Workflow

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Workflow, 2023 & 2032 (%)
    • 8.1.2. Upstream Manufacturing
      • 8.1.2.1. Vector Amplification & Expansion
      • 8.1.2.2. Vector Recovery/Harvesting
    • 8.1.3. Downstream Manufacturing
      • 8.1.3.1. Purification
      • 8.1.3.2. Fill Finish

9. Viral Vector and Plasmid DNA Manufacturing Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 9.1.2. Antisense & RNAi Therapy
    • 9.1.3. Vaccinology
    • 9.1.4. Gene Therapy
    • 9.1.5. Tissue Engineering
    • 9.1.6. Cell Therapy
    • 9.1.7. Research Applications
    • 9.1.8. Others (Biosensors, etc.)

10. Viral Vector and Plasmid DNA Manufacturing Market - By End-use

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-use, 2023 & 2032 (%)
    • 10.1.2. Pharmaceutical and Biopharmaceutical Companies
    • 10.1.3. Contract Manufacturing Organizations (CMOs)
    • 10.1.4. Research Institutes
    • 10.1.5. Others (Government Agencies, etc.)

11. Viral Vector and Plasmid DNA Manufacturing Market - By Therapeutic Area

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Therapeutic Area, 2023 & 2032 (%)
    • 11.1.2. Neurological Disorders
    • 11.1.3. Sensory Disorders
    • 11.1.4. Musculoskeletal Disorders
    • 11.1.5. Metabolic Disorders
    • 11.1.6. Oncological Disorders
    • 11.1.7. Rare Diseases
    • 11.1.8. Blood Disorders
    • 11.1.9. Immunological Disorders
    • 11.1.10. Others (Reproductive Health, etc.)

12. Viral Vector and Plasmid DNA Manufacturing Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Viral Vector and Plasmid DNA Manufacturing Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. CEVEC Pharmaceuticals
    • 13.2.2. Catalent Biologics
    • 13.2.3. Cobra Biologics
    • 13.2.4. Altruist Biotechnology
    • 13.2.5. NorthX Biologics
    • 13.2.6. Novartis
    • 13.2.7. BioReliance (a subsidiary of Merck KGaA)
    • 13.2.8. Centre for Process Innovation
    • 13.2.9. Wuxi AppTech
    • 13.2.10. Charles River Laboratories
    • 13.2.11. CoJourney
    • 13.2.12. Esco Aster
    • 13.2.13. Jiangsu Puxin Biopharmaceutical
    • 13.2.14. Lonza
    • 13.2.15. Advanced BioScience Laboratories
    • 13.2.16. AGC Biologics
    • 13.2.17. Aldevron
    • 13.2.18. Biovian
    • 13.2.19. Celonic
    • 13.2.20. BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)
    • 13.2.21. Oxford BioMedica
    • 13.2.22. Sanofi
    • 13.2.23. Thermo Fisher Scientific
    • 13.2.24. VectorBuilder
    • 13.2.25. Matica Biotechnology
    • 13.2.26. Resilience
    • 13.2.27. Nikon CeLL innovation

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Vector Type Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Vector Type
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Workflow Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Workflow
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Workflow 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Application Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Application
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Application 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: End-use Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by End-use
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by End-use 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Therapeutic Area Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Therapeutic Area
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Region 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by End-use, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by End-use, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by End-use, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by End-use, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by End-use, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area, 2019-2032 (USD Million)